{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:18:48Z","timestamp":1784989128662,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["RS-2023-00217189"],"award-info":[{"award-number":["RS-2023-00217189"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2022R1A2C2006322"],"award-info":[{"award-number":["2022R1A2C2006322"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.pathol.2024.02.012","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T08:33:09Z","timestamp":1714984389000},"page":"653-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Detection of EGFR exon 20 insertion mutations in non-small cell lung cancer: implications for consistent nomenclature in precision medicine"],"prefix":"10.1016","volume":"56","author":[{"given":"Jieun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7784-5971","authenticated-orcid":false,"given":"Boram","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Young","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjung","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Jeong","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae Rin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangjin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Kee","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5788-5140","authenticated-orcid":false,"given":"Yoon-La","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2024.02.012_bib1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1590\/1414-431X20144099","article-title":"Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data","volume":"47","author":"Jorge","year":"2014","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.pathol.2024.02.012_bib2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3892\/or.2017.5409","article-title":"Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung\u00a0cancer: perplexity and solution","volume":"37","author":"Li","year":"2017","journal-title":"Oncol Rep"},{"key":"10.1016\/j.pathol.2024.02.012_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4132\/jptm.2022.06.11","article-title":"Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing","volume":"56","author":"Lee","year":"2022","journal-title":"J\u00a0Pathol Transl Med"},{"key":"10.1016\/j.pathol.2024.02.012_bib4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4143\/crt.2022.381","article-title":"Real-world study of osimertinib in Korean patients with epidermal growth factor receptor T790M mutation\u2013positive non\u2013small cell lung cancer","volume":"55","author":"Lee","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.pathol.2024.02.012_bib5","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.pathol.2021.01.017","article-title":"EGFR mutation profile in Australian patients with non-small cell lung cancer","volume":"53","author":"Mead","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2024.02.012_bib6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.6004\/jnccn.2021.5020","article-title":"Non\u2013small cell lung cancer: recommendations for biomarker testing and treatment","volume":"19","author":"Aisner","year":"2021","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.pathol.2024.02.012_bib7","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.21037\/tcr.2020.03.10","article-title":"EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"9","author":"Wang","year":"2020","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.pathol.2024.02.012_bib8","doi-asserted-by":"crossref","first-page":"E8162","DOI":"10.1073\/pnas.1803152115","article-title":"Altered conformational landscape and dimerization dependency underpins the activation of EGFR by alphaC-beta4 loop insertion mutations","volume":"115","author":"Ruan","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2024.02.012_bib9","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1158\/2159-8290.CD-21-0226","article-title":"Targeting EGFR exon 20 insertions in non\u2013small cell lung cancer: recent advances and clinical updates","volume":"11","author":"Meador","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pathol.2024.02.012_bib10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2021.10.020","article-title":"Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations","volume":"162","author":"Bazhenova","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.pathol.2024.02.012_bib11","doi-asserted-by":"crossref","first-page":"e859","DOI":"10.1016\/j.cllc.2021.04.009","article-title":"EGFR exon 20 insertion mutations: clinicopathological characteristics and treatment outcomes in advanced non-small cell lung cancer","volume":"22","author":"Leal","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.pathol.2024.02.012_bib12","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/1078-0432.CCR-22-2072","article-title":"FDA approval summary: mobocertinib for metastatic non\u2013small cell lung cancer with EGFR exon 20 insertion mutations","volume":"29","author":"Duke","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2024.02.012_bib13","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-021-01561-7","article-title":"Amivantamab: first approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.pathol.2024.02.012_bib14","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/2159-8290.CD-21-1615","article-title":"Sunvozertinib, a selective EGFR\u00a0inhibitor for previously treated non-small cell lung cancer with\u00a0EGFR exon 20 insertion mutations","volume":"12","author":"Wang","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pathol.2024.02.012_bib15","doi-asserted-by":"crossref","first-page":"S1663","DOI":"10.1016\/j.annonc.2023.10.586","article-title":"507O EXCLAIM-2: phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced\/metastatic NSCLC","volume":"34","author":"J\u00e4nne","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2024.02.012_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221146131","article-title":"Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations","volume":"15","author":"Low","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.pathol.2024.02.012_bib17","article-title":"Not All EGFR exon 20 insertions are created equal","volume":"1","author":"Lin","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.pathol.2024.02.012_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20\u00a0insertion mutations in lung cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pathol.2024.02.012_bib19","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ccell.2022.06.006","article-title":"Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity","volume":"40","author":"Elamin","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pathol.2024.02.012_bib20","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 Update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum Mutat"},{"key":"10.1016\/j.pathol.2024.02.012_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13073-016-0396-7","article-title":"A\u00a0variant by any name: quantifying annotation discordance across tools and clinical databases","volume":"9","author":"Yen","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.pathol.2024.02.012_bib22","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/1878-0261.12710","article-title":"Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors","volume":"14","author":"Qin","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.pathol.2024.02.012_bib23","first-page":"845","article-title":"A\u00a0case of advanced lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) exon 20 insertion, D770_N771insSVD","volume":"48","author":"Oyamada","year":"2021","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.pathol.2024.02.012_bib24","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jtho.2023.01.086","article-title":"Distribution and detectability of EGFR exon 20 insertion variants in NSCLC","volume":"18","author":"Ou","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2024.02.012_bib25","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2024.02.012_bib26","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jtho.2020.05.002","article-title":"The International Association for the Study of Lung Cancer global survey on molecular testing in lung cancer","volume":"15","author":"Smeltzer","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2024.02.012_bib27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","article-title":"The Eighth edition lung cancer stage classification","volume":"151","author":"Detterbeck","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.pathol.2024.02.012_bib28","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1016\/j.jtho.2021.01.112","article-title":"FP07.12 underdiagnosis of EGFR exon 20 insertion mutation variants: estimates from NGS-based real-world datasets","volume":"16","author":"Bauml","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2024.02.012_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.4761","article-title":"Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1\/2 open-label nonrandomized clinical trial","volume":"7","author":"Zhou","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pathol.2024.02.012_bib30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4143\/crt.2023.800","article-title":"Next-generation sequencing in breast cancer patients: real-world data for precision medicine","volume":"56","author":"Lee","year":"2024","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.pathol.2024.02.012_bib31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.pathol.2024.02.012_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2019.10.030","article-title":"Detection of rare and novel EGFR mutations in NSCLC patients: implications for treatment-decision","volume":"139","author":"Sousa","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.pathol.2024.02.012_bib33","article-title":"A\u00a0performance evaluation study: variant annotation tools - the enigma of clinical next generation sequencing (NGS) based genetic testing","volume":"13","author":"Tuteja","year":"2022","journal-title":"J\u00a0Pathol Inform"},{"key":"10.1016\/j.pathol.2024.02.012_bib34","doi-asserted-by":"crossref","first-page":"S680","DOI":"10.1016\/j.jtho.2019.08.1443","article-title":"P2.01-100 spectrum of EGFR exon 20 insertion mutations and co-occurring genetic alterations in patients with non-small-cell lung cancer","volume":"14","author":"Montenegro","year":"2019","journal-title":"J\u00a0Thor Oncol"},{"key":"10.1016\/j.pathol.2024.02.012_bib35","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jtho.2023.01.086","article-title":"Distribution and detectability of EGFR exon 20 insertion variants in NSCLC","volume":"18","author":"Ou","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2024.02.012_bib36","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2024.02.012_bib37","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2024.02.012_bib38","doi-asserted-by":"crossref","first-page":"S690","DOI":"10.1016\/j.jtho.2021.01.1271","article-title":"P89.06 Prospective concordance study of a multi-gene PCR assay and NGS for the detection of targetable gene alterations in lung cancer","volume":"16","author":"Matsumoto","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2024.02.012_bib39","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jval.2020.03.005","article-title":"Impact of next generation sequencing on clinical practice in oncology in France: better genetic profiles for patients improve access to experimental treatments","volume":"23","author":"Coquerelle","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.pathol.2024.02.012_bib40","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/annonc\/mdv208","article-title":"Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer","volume":"26","author":"Lim","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2024.02.012_bib41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/gb-2011-12-8-125","article-title":"The real cost of sequencing: higher than you think","volume":"12","author":"Sboner","year":"2011","journal-title":"Genome Biol"},{"key":"10.1016\/j.pathol.2024.02.012_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.lungcan.2022.11.009","article-title":"Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: an international observational study","volume":"175","author":"Subramanian","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.pathol.2024.02.012_bib43","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jtho.2022.10.021","article-title":"Expert consensus recommendations on biomarker testing in metastatic and nonmetastatic NSCLC in Asia","volume":"18","author":"Mitsudomi","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2024.02.012_bib44","article-title":"EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302524001235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302524001235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T20:52:44Z","timestamp":1720126364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302524001235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0031302524001235"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2024.02.012","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of EGFR exon 20 insertion mutations in non-small cell lung cancer: implications for consistent nomenclature in precision medicine","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2024.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}